GTS5:Table of Contents: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 23: | Line 23: | ||
- [[GTS5:Carney complex (PRKAR1A, PDE8B, PDE11A)]] | - [[GTS5:Carney complex (PRKAR1A, PDE8B, PDE11A)]] | ||
- [[GTS5:PROS syndrome (PIK3CA)]] | - [[GTS5:PROS syndrome (PIK3CA)]] | ||
'''WNT/TGFbeta pathway''' | '''WNT/TGFbeta pathway''' | ||
- [[GTS5:Familial adenomatous polyposis (APC)]] | - [[GTS5:Familial adenomatous polyposis (APC)]] | ||
| Line 50: | Line 50: | ||
- [[GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]] | - [[GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]] | ||
'''Transcription factors and regulators''' | '''Transcription factors and regulators''' | ||
- [[GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]] | - [[GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]] | ||
- [[GTS5:MAFA-related familial insulinomatosis (MAFA)]] | - [[GTS5:MAFA-related familial insulinomatosis (MAFA)]] | ||
| Line 60: | Line 59: | ||
==Oxidative stress response and metabolism ([[GTS5:Oxidative stress response and metabolism|Overview Page Link]])== | ==Oxidative stress response and metabolism ([[GTS5:Oxidative stress response and metabolism|Overview Page Link]])== | ||
'''Angiogenesis''' | '''Angiogenesis''' | ||
- [[GTS5:Von Hippel-Lindau syndrome (VHL)]] | - [[GTS5:Von Hippel-Lindau syndrome (VHL)]] | ||
| Line 67: | Line 66: | ||
- [[GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]] | - [[GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]] | ||
'''Toxic metabolite-mediated disorders''' | |||
- [[GTS5:Hereditary tyrosinaemia type 1 (FAH)]] | - [[GTS5:Hereditary tyrosinaemia type 1 (FAH)]] | ||
==Cell cycle and apoptosis pathways ([[GTS5:Cell cycle and apoptosis pathways|Overview Page Link]])== | ==Cell cycle and apoptosis pathways ([[GTS5:Cell cycle and apoptosis pathways|Overview Page Link]])== | ||
'''P53 pathway''' | '''P53 pathway''' | ||
- [[GTS5:Li-Fraumeni syndrome (TP53)]] | - [[GTS5:Li-Fraumeni syndrome (TP53)]] | ||
| Line 85: | Line 84: | ||
==DNA repair and genomic stability ([[GTS5:DNA repair and genomic stability|Overview Page Link]])== | ==DNA repair and genomic stability ([[GTS5:DNA repair and genomic stability|Overview Page Link]])== | ||
'''Mismatch repair''' | '''Mismatch repair''' | ||
- [[GTS5:Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]] | - [[GTS5:Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]] | ||
| Line 91: | Line 91: | ||
'''Homologous recombination''' | '''Homologous recombination''' | ||
- [[GTS5:BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)]] | - [[GTS5:BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)]] | ||
- [[GTS5:PALB2-related cancer predisposition syndrome (PALB2)]] | - [[GTS5:PALB2-related cancer predisposition syndrome (PALB2)]] | ||
| Line 126: | Line 125: | ||
==Telomere maintenance ([[GTS5:Telomere maintenance|Overview Page Link]])== | ==Telomere maintenance ([[GTS5:Telomere maintenance|Overview Page Link]])== | ||
'''Telomere biology disorders''' | '''Telomere biology disorders''' | ||
- [[GTS5:Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]] | - [[GTS5:Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]] | ||
| Line 132: | Line 132: | ||
==Epigenetic drivers and chromatin remodelling ([[GTS5:pigenetic drivers and chromatin remodelling|Overview Page Link]])== | ==Epigenetic drivers and chromatin remodelling ([[GTS5:pigenetic drivers and chromatin remodelling|Overview Page Link]])== | ||
'''Imprinting disorders''' | '''Imprinting disorders''' | ||
- [[GTS5:Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]] | - [[GTS5:Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]] | ||
| Line 146: | Line 146: | ||
==RNA regulation ([[GTS5:RNA regulation|Overview Page Link]])== | ==RNA regulation ([[GTS5:RNA regulation|Overview Page Link]])== | ||
'''MicroRNA''' | '''MicroRNA''' | ||
- [[GTS5:DICER1-related tumour predisposition syndrome (DICER1)]] | - [[GTS5:DICER1-related tumour predisposition syndrome (DICER1)]] | ||
- [[GTS5:MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8)]] | - [[GTS5:MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8)]] | ||
| Line 155: | Line 155: | ||
==Protein regulation ([[GTS5:Protein regulation|Overview Page Link]])== | ==Protein regulation ([[GTS5:Protein regulation|Overview Page Link]])== | ||
'''Ubiquitin pathway''' | '''Ubiquitin pathway''' | ||
- [[GTS5:BAP1-related tumour predisposition syndrome (BAP1)]] | - [[GTS5:BAP1-related tumour predisposition syndrome (BAP1)]] | ||